Cumberland Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Cumberland Pharmaceuticals has a total shareholder equity of $28.3M and total debt of $5.2M, which brings its debt-to-equity ratio to 18.5%. Its total assets and total liabilities are $69.9M and $41.6M respectively.
Key information
18.49%
Debt to equity ratio
US$5.24m
Debt
| Interest coverage ratio | n/a |
| Cash | US$15.11m |
| Equity | US$28.34m |
| Total liabilities | US$41.60m |
| Total assets | US$69.94m |
Recent financial health updates
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Feb 21
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 04Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Mar 07Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Aug 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Mar 18Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 02Recent updates
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30%
May 13Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 117%
Mar 01Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Feb 21Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified
Jan 15Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 04Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Mar 07Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares
Jan 09Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S
Oct 02Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Aug 10Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet?
Mar 18Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Nov 02Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Jul 20Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt?
Apr 15Checking In On Cumberland Pharmaceuticals
Jan 04Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt?
Nov 09We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation
Apr 21Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way?
Feb 13One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts
Nov 19
Financial Position Analysis
Short Term Liabilities: CPIX's short term assets ($31.9M) exceed its short term liabilities ($25.5M).
Long Term Liabilities: CPIX's short term assets ($31.9M) exceed its long term liabilities ($16.1M).
Debt to Equity History and Analysis
Debt Level: CPIX has more cash than its total debt.
Reducing Debt: CPIX's debt to equity ratio has reduced from 37.1% to 18.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CPIX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CPIX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 6.6% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/02 16:52 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cumberland Pharmaceuticals Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| Irina Rivkind Koffler | Duncan-Williams, Inc. |
| David Windley | Jefferies LLC |